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SHIV-89.6PThe recently reported modest success of the RV144 Thai trial vaccine regimen in preventing HIV-1 acquisition
has focused interest on the potential contribution to that protection of vaccine-elicited CD4+ T cell responses.
We evaluated the induction of virus-speciﬁc CD4+ T cell responses in rhesus monkeys using a series of diverse
vaccine vectors. We assessed both the magnitudes and functional proﬁles of the antigen-speciﬁc CD4+ T cells
by measuring cytokine production, memory differentiation, and the expression of mucosal homingmolecules.
We found that DNAprime/recombinantMVAboost immunizations induced particularly high-frequency virus-
speciﬁc CD4+ T cell responses with polyfunctional repertoires, and these responses were partially preserved
following SHIV-89.6P challenge. The majority of the vaccine-elicited CD4+ T cells were CD28+memory T cells
that expressed low levels of β7. Neither themagnitudes nor the functional proﬁles of the virus-speciﬁc CD4+ T
cells generated by vaccinationwere associatedwith a preservation of CD4+T cells or control of viral replication
following SHIV-89.6P challenge. Interestingly, monkeys primedwith recombinant Ad5 immunogens showed a
dramatic expansion of both the magnitude and polyfunctionality of the vaccine-elicited CD4+ T cell responses
following envelope protein boost. These results demonstrate that vaccine strategies that include recombinant
MVA or recombinant Ad5 vectors can elicit robust CD4+ T cell responses.sis, Department of Medicine,
School, Center for Life Science,
617 735 4527.
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The ﬁndings in the recently reported HIV-1 vaccine trial in Thailand
(RV144) have refocused interest on vaccine-elicited CD4+ T cell and
antibody responses. In this human vaccine trial, a recombinant
canarypox priming immunization followed by an envelope protein
boosting immunization generated modest protection against the
acquisition of an HIV-1 infection (Rerks-Ngarm et al., 2009). Since this
vaccine regimen elicited CD4+ T cell and antibody responses but not
CD8+ T cell responses, attention is turning to the evaluation of vaccine
strategies that induce robust and durable responses of these types.
Virus-speciﬁc CD4+ T cells play a central role in the immune
containment of HIV-1. They contribute to HIV-1 clearance both by
providing help for B cell responses and by maintaining effective
cytotoxic T lymphocytes (CTLs) (Kalams and Walker, 1998). Func-
tional CD4+ T cells are also required at the time of immune priming
for the normal development of memory CD8+ T cells (Janssen et al.,
2003; Shedlock and Shen, 2003). It is therefore important to explore
vaccine strategies for eliciting antigen-speciﬁc CD4+ T cell responses.While the evaluation of HIV-1 vaccine candidates has, for the most
part, relied on determining the magnitude of vaccine-elicited T
lymphocyte IFN-γ responses, emerging data are indicating that
different vaccine modalities can induce cellular immune responses
that are qualitatively very different (Casimiro et al., 2003; Cox et al.,
2008; Hansen et al., 2009; Hovav et al., 2007; Sun et al., 2008). For
example, some vaccine modalities bias T cells to central memory and
others to effector memory responses. Moreover, different vaccine
platforms induce T lymphocyte responses with different functional
proﬁles. It will be important to evaluate diverse characteristics of
vaccine-induced CD4+ T cell responses.
The present study was initiated to explore quantitative and
qualitative differences in the virus-speciﬁc CD4+ T cell responses
generated in rhesus monkeys using different vaccine modalities. We
had the opportunity to carry out an evaluation of these immune
responses elicited by different vaccine vectors expressing the same
HIV and SIV gene inserts.
Results
Study design
The immunization and challenge schedule for each experimental
group of monkeys is summarized in Table 1 (Letvin et al., 2004; Letvin
et al., 2006; Santra et al., 2004, 2007, 2009; Seaman et al., 2005). In the
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1012 particles of rAd5 as a priming immunization at weeks 0 and 8,
followed by a homologous rAd5 boost at week 26. Six monkeys
received 109 pfu of recombinant MVA at weeks 0 and 8, followed by
homologous boosting immunizations at weeks 26 and 43. Another 4
monkeys received 5mg plasmid DNA at weeks 0, 4, and 8, followed by
a homologous DNA plasmid boosting immunization at week 42. In the
heterologous DNA-rAd5 experimental group, 17 monkeys received
4 mg inoculations of plasmid DNA at weeks 0, 4, and 8 followed by a
heterologous rAd5 boosting immunization atweek 26. Twelvemonkeys
in the DNA–rMVA experimental group received 5 mg inoculations of
plasmid DNA at weeks 0, 4, and 8 followed by a heterologous
recombinant MVA boosting immunization at week 42. Six monkeys in
the rAd5-protein group received 1011 particles of rAd5 as a priming
immunization at weeks 0 and 3, followed by an HIV-1 envelope protein
boost (SF162 gp140 delta V2) at week 39. At 12 weeks (DNA-rAd5),
18 weeks (DNA–rMVA, DNA–DNA), 21 weeks (rMVA–rMVA), or
22 weeks (rAd5–rAd5) after the ﬁnal immunizations, ﬁve groups of
experimental and 14 control monkeys were challenged intravenously
with ﬁfty 50% monkey infectious doses of pathogenic SHIV-89.6P from
the same virus stock.
Virus-speciﬁc CD4+ T cell responses following vaccination and following
SHIV-89.6P challenge
We ﬁrst sought to characterize the virus-speciﬁc CD4+ T cell
responses elicited by various well-established vaccine vectors. PBMCs
from monkeys receiving homologous or heterologous vaccination
regimens were isolated at 2 weeks following priming immunization
(prime, peak), 12 weeks following boosting immunization (boost,
plateau), 2 weeks following challenge (challenge, peak), and 12 weeks
following challenge (challenge, plateau). PBMCs were exposed to
pools of overlapping peptides spanning the SIV Gag or HIV-1 Env
protein, and the fractions of CD4+ T cells producing IFN-γ, TNF-α, or
IL-2 were determined by intracellular cytokine staining (Fig. 1).
Very few virus-speciﬁc CD4+ T cellswere detected inmonkeys that
received a rAd5 or rMVA priming immunization. In contrast, monkeys
primedwith plasmidDNAdeveloped substantial virus-speciﬁc CD4+ T
cell responses that could be measured by IFN-γ, TNF-α, or IL-2
production. Homologous rAd5, rMVA, or DNA boosting elicited no
further increase in the magnitude of the virus-speciﬁc CD4+ T cell
responses. However, the monkeys that received DNA immunizations
developed a dramatic expansion of their virus-speciﬁc CD4+ T cell
responses following a heterologous rMVA boosting. A substantial
expansion of virus-speciﬁc CD4+ T cell responses was also seen after
heterologous rAd5 boosting. Of the vaccine regimens that we
evaluated, DNA prime, heterologous rMVA boost immunization
elicited the highest frequency virus-speciﬁc CD4+ T cell responses.
We then sought to evaluate whether these different vaccination
regimens affected the magnitude of the CD4+ T cell responses that
developed in these monkeys following a SHIV challenge (Fig. 1, lower
two panels). The virus-speciﬁc CD4+ T cell responses of these groups
of vaccinated monkeys fell 2 weeks after challenge, consistent withTable 1
Immunization and challenge schedule.
Group Priming immunization Boosting immunization
rAd5–rAd5 (n=6) rAd5, 1012 particles; weeks 0 and 8 rAd5, 1012 particles; we
rMVA–rMVA (n=6) rMVA, 109 pfu; weeks 0 and 8 rMVA, 109 pfu; weeks 2
DNA–DNA (n=4) DNA, 5 mg; weeks 0, 4 and 8
IL-2/Ig plasmid, 5 mg; weeks 0 and 4
DNA, 5 mg; week 42
DNA–rAd5 (n=17) DNA, 4 mg; weeks 0, 4 and 8 rAd5, 1012 particles; we
DNA–rMVA (n=12) DNA, 5 mg; weeks 0, 4 and 8
IL-2/Ig plasmid, 5 mg; weeks 0 and 4
rMVA, 109 pfu; week 42
rAd5–protein (n=6) rAd5, 1011 particles; weeks 0 and 3 HIV-1 SF162 gp140, 100the well-described loss of naïve CD4+ T cells during the ﬁrst 2 weeks
after SHIV-89.6P infection (Nishimura et al., 2005). However, these
virus-speciﬁc CD4+ T cell responses returned to baseline levels
12 weeks following SHIV-89.6P challenge. As expected, the control
monkeys only generated low frequency virus-speciﬁc CD4+ T cell
responses following challenge. Twelve weeks following SHIV-89.6P
challenge, highly signiﬁcant differences were found between the
magnitudes of the CD4+ T cell responses in the control monkeys and
the groups of monkeys receiving DNA prime/recombinant viral vector
boost vaccinations (Kruskal–Wallis tests, Pb0.01).
Functional proﬁles of virus-speciﬁc CD4+ T cells following vaccination
and following SHIV-89.6P challenge
We previously showed that heterologous prime–boost vaccine
regimens induced high-frequency virus-speciﬁc CD8+ T cell responses
with polyfunctional repertoires. Moreover, the functional proﬁles of the
vaccine-induced virus-speciﬁc CD8+T cellswere associatedwith control
of viral replication following SHIV-89.6P challenge (Sun et al., 2008).We
wanted to determinewhether these different vaccine strategies induced
qualitatively different virus-speciﬁc CD4+ T cell responses. Total virus-
speciﬁc cytokine-producing CD4+ T cells were divided into seven
distinct populations based on their production of IFN-γ, TNF-α, and IL-2,
either individually or in any combination. The functional proﬁles of the
vaccine-induced CD4+ T cells are shown by expressing each type of
cytokine response as a proportion of the total response. Themean values
for the animals in each experimentally vaccinated group are shown in a
series of pie charts (Fig. 2).
Monkeys primed with rAd5 or DNA developed polyfunctional
virus-speciﬁc CD4+ T cell responses that were predominantly
cytokine triple positive or cytokine double positive (IFN-γ+TNF-
α+IL-2− and IFN-γ−TNF-α+IL-2+). Homologous or heterologous
boosting did not further expand the representation of polyfunctional
virus-speciﬁc CD4+ T cell responses. In addition, the cytokine proﬁles
of the virus-speciﬁc CD4+ T cells of these groups of vaccinated
monkeys were indistinguishable 12 weeks following SHIV-89.6P
challenge, with most cells being IL-2−IFN-γ+TNF-α+ (Fig. 2, lower
two panels). Moreover, no signiﬁcant differences were found between
the control and vaccinated groups in the representation of polyfunc-
tional virus-speciﬁc CD4+ T cells observed following SHIV-89.6P
challenge.
Expression of memory- and mucosal homing-associated molecules on
virus-speciﬁc CD4+ T cells following vaccination and following challenge
Having failed to detect a qualitative difference in the cytokine
proﬁles of the virus-speciﬁc CD4+T cell elicitedby these various vaccine
regimens, we sought to determine whether these different vaccine
regimens induced qualitatively different virus-speciﬁc CD4+ T cell
responses asmeasured byβ7 and CD28 expression (Fig. 3).β7-Integrins
are expressed on mucosal lymphocytes and mediate lymphocyte
trafﬁcking to and retention in mucosal tissues (Gorfu et al., 2009). We
therefore evaluated the expression of β7 on virus-speciﬁc CD4+ T cellsSHIV-89.6P challenge Reference
ek 26 week 48 Santra et al. (2009)
6 and 43 week 64 Santra et al. (2007)
week 60 Santra et al. (2004)
ek 26 week 38 Letvin et al. (2004)
Letvin et al. (2006)
week 60 Santra et al. (2004)
μg adjuvanted with MF59; week 39 2 2
Fig. 1. Antigen-speciﬁc CD4+ T cell responses following vaccination and following SHIV-89.6P challenge. Peripheral blood lymphocytes from monkeys receiving homologous (rAd5/rAd5,
rMVA/rMVA, DNA/DNA) or heterologous vaccination regimens (DNA/rAd5, DNA/rMVA)were exposed to pools of overlapping peptides spanning the SIV Gag or HIV-1 Env protein and the
fractions of CD4+T cells producing IFN-γ, TNF-α, or IL-2 are shown in theupper twopanels. All experimental and14 controlmonkeyswere then challengedwith SHIV-89.6P, and the antigen-
speciﬁc CD4+ T cell responses that developed in these monkeys following challenge are shown in the lower two panels.
Fig. 2. Cytokine proﬁles of antigen-speciﬁc CD4+ T cells following vaccination and following SHIV-89.6P challenge. PBL isolated from the different cohorts of rhesus monkeys at the
indicated times following vaccination and following virus challenge were exposed to pools of overlapping peptides spanning the Gag or Env proteins and cytokine production was
measured by intracellular cytokine staining. Antigen-speciﬁc cytokine-producing CD4+ T cellswere divided into sevendistinct populations based on their production of IFN-γ, TNF-α, and
IL-2 either individually or in any combination. Cytokine proﬁles were determined by expressing each cytokine response as a proportion of the total antigen-speciﬁc cytokine-producing
CD4+ T cell response, and data are presented as the mean values from each experimental group in a pie chart.
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Fig. 3. Expression of memory- and mucosal homing-associated molecules on antigen-speciﬁc CD4+ T cells following vaccination and following challenge. PBL isolated from the
different cohorts of rhesus monkeys at the indicated times following vaccination or challenge were exposed to pools of overlapping peptides spanning the Gag or Env proteins, and
the fractions of CD4+ T cells producing IFN-γ, TNF-α, or IL-2 were determined by intracellular cytokine staining. The sum total production of all three cytokines was determined by
ﬂow cytometric analysis. Expression of CD28 (memory-associated molecule) and β7 (mucosal homing-associated molecule) on these antigen-speciﬁc cytokine-producing CD4+ T
cells is presented as mean±SEM.
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monkeys. Few virus-speciﬁc CD4+ T cells expressed β7 after rAd5 or
DNA priming. Homologous or heterologous boost immunization did not
expand the proportion of β7+ virus-speciﬁc CD4+ T cells. Therefore,
virus-speciﬁc CD4+ T cells elicited by vaccination expressed low levels
of this mucosal homing molecule. However, approximately 20%–30% of
the virus-speciﬁc CD4+ T cells began to express β7 after SHIV-89.6P
challenge, and no signiﬁcant differences were detected between the
control and vaccinated animals. A detailed phenotypic analysis was also
done to assess thememory differentiation of thesevirus-speciﬁc CD4+T
cells. Virus-speciﬁc CD4+ T cells were divided into central and effector
memory cells based on their expression of CD28 (Pitcher et al., 2002).
Interestingly, virus-speciﬁc CD4+ T cells were predominantly CD28+
memory cells, and no signiﬁcant differences were detected in the
relative representation of these CD28+CD4+ T cells between the
different groups of animals following vaccination and following
challenge.
Magnitude and quality of vaccine-induced virus-speciﬁc CD4+ T cell
responses were not associated with preservation of CD4+ T cells and
control of viral replication following SHIV-89.6P challenge
We have previously shown that both the magnitude and
functional proﬁle of the virus-speciﬁc CD8+ T cells generated by
vaccination were associated with control of viral replication following
SHIV-89.6P challenge (Sun et al., 2008). In the current study, we
evaluated whether an association also exists between the magnitude
and quality of vaccine-elicited virus-speciﬁc CD4+ T cell responses
and disease progression following viral infection. To evaluate this
possibility, we divided all 33 animals that received experimental
vaccines into halves, low and high, on the basis of the magnitudes oftheir CD4+ T cell counts, as well as the magnitudes of their peak and
their plateau plasma viral RNA levels. Both the quantity and quality of
virus-speciﬁc CD4+ T cell responses after the boost immunizations
were then compared in these cohorts (Fig. 4). The vaccine-elicited
virus-speciﬁc CD4+ T cells were of comparable magnitudes and had
comparable functional proﬁles in animals that demonstrated low or
high set point CD4+ T cell counts post-challenge. Furthermore, the
vaccine-elicited virus-speciﬁc CD4+ T cells were also comparable in
the monkeys with low or high peak and set point viral RNA levels.
Thus, neither the magnitudes nor the functional proﬁles of the virus-
speciﬁc CD4+ T cells generated by vaccination were associated with a
preservation of CD4+ T cells or control of viral replication following
SHIV-89.6P challenge.
rAd5 prime, envelope protein boost induced high-frequency envelope-
speciﬁc CD4+ T cell responses with polyfunctional repertoires
In the recently reported RV144 HIV-1 vaccine trial in Thailand, a
recombinant canarypox priming immunization followed by an
envelope protein boosting immunization generated modest protec-
tion against acquiring an HIV-1 infection (Rerks-Ngarm et al., 2009).
We were therefore interested to evaluate both the magnitude and
functional proﬁle of the vaccine-elicited envelope-speciﬁc CD4+ T cell
responses in six rhesus monkeys that received a recombinant vector
priming immunization followed by an HIV-1 envelope boosting
immunization.
Monkeys primed with rAd5 developed envelope-speciﬁc T cell
responses that included both CD4+ and CD8+ T cells (Fig. 5A).
However, a dramatic CD4+ T cell-biased expansion of envelope-
speciﬁc T cell responses was seen 2 weeks after the envelope protein
boost. We then analyzed the functional proﬁle of these envelope-
Fig. 4.Magnitude and functionality of the vaccine-elicited antigen-speciﬁc CD4+ T cell responses were not associated with preserved CD4+ T cells or reduced plasma viral RNA levels
following SHIV-89.6P challenge. The 33 animals that received different vaccine regimens were divided into halves, low and high, based on themagnitudes of their plateau CD4+ T cell
counts (A), peak plasma viral RNA levels (B), or plateau plasma viral RNA levels (C). PBL isolated following the boost immunizations were exposed to pools of overlapping peptides
spanning the Gag or Env proteins, and the fractions of CD4+ T cells producing IFN-γ, TNF-α, or IL-2 were determined by intracellular cytokine staining. In the left panels, the
magnitudes of the vaccine-elicited antigen-speciﬁc CD4+ T cell responses are presented as means±SEM in bar charts. In the right panels, functional proﬁles of the vaccine-elicited
antigen-speciﬁc CD4+ T cells are shown as the mean values from each group of monkeys in pie charts.
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polyfunctional envelope-speciﬁc CD4+ T cell responses that were
predominantly IFN-γ+TNF-α+IL-2+ or IFN-γ+TNF-α+IL-2−. Enve-
lope protein boosting induced a further expansion of the polyfunc-
tional envelope-speciﬁc CD4+ T cell responses, with 75% of the
responses made up of either cytokine double-positive or triple-
positive CD4+ T cells. Further, the cytokine proﬁles of these cells were
unchanged 12 weeks following the boost immunization. A detailed
phenotypic analysis was also done to assess the memory differenti-
ation of these envelope-speciﬁc CD4+ T cells. Consistent with
previous results, the envelope-speciﬁc CD4+ T cells elicited by the
protein boosting immunization were predominantly CD28+ memory
cells (Fig. 5B). These results indicate that rAd5 prime/envelope
protein boost immunization induced high-frequency envelope-spe-
ciﬁc CD28+ memory CD4+ T cell responses with polyfunctional
repertoires.
Discussion
In the wake of the recently reported modest success of the RV144
Thai vaccine trial, interest has turned to the potential contribution of
vaccine-elicited CD4+ T cell and antibody responses to protection
against HIV-1 acquisition. In the current study, we found that different
vectors generated virus-speciﬁc CD4+ T cell responses of different
magnitudes and with different functional proﬁles. Of the vaccine
regimens that we evaluated, DNA prime/rMVA boost immunization
elicited the highest-frequency virus-speciﬁc CD4+ T cell responses,
and these cells had polyfunctional repertoires. A substantial expan-sion of the virus-speciﬁc CD4+ T cell responses was also seen in
plasmid DNA primed monkeys after rAd5 boosting.
Immediately after a SHIV-89.6P challenge, the virus-speciﬁc CD4+
T cell populations in these vaccinated monkeys decreased, likely as a
consequence of the well-described loss of CD4+ T cells during the ﬁrst
weeks following a pathogenic CXCR4-tropic SHIV infection (Nishimura
et al., 2005). Although these virus-speciﬁc CD4+ T cell responses
decreased followingSHIV-89.6P challenge, highly signiﬁcantdifferences
were observed between the magnitudes of these responses in the
controlmonkeys and groups ofmonkeys receiving heterologous prime–
boost vaccinations. These results demonstrate that immunization by
DNA prime, heterologous vector boost induced high frequency HIV-1-
and SIV-speciﬁc CD4+ T cell responses that are partially preserved
following an intravenous infection with a pathogenic CXCR4-tropic
SHIV.
We also evaluated the expression of memory- and mucosal
homing-associated molecules on SIV-speciﬁc CD4+ T cells following
vaccination and following SHIV-89.6P challenge.We found that after a
priming immunization very few of the virus-speciﬁc CD4+ T cells
expressed β7, the mucosal homing-associated molecule. Moreover, a
homologous or heterologous boosting immunization did not expand
the proportion of β7+ virus-speciﬁc CD4+ T cells. Therefore, virus-
speciﬁc CD4+ T cells elicited by vaccination expressed low levels of
this mucosal homing molecule. A detailed memory phenotypic
analysis showed that majority of the virus-speciﬁc CD4+ T cells
elicited by vaccination were CD28+ central memory T cells, and no
signiﬁcant differences were detected in the relative representation of
these CD28+CD4+ T cells in the various groups of animals following
Fig. 5. HIV-1 envelope-speciﬁc CD4+ T cell responses following rAd5 prime and envelope protein boost. (A) PBL from six animals that received a rAd5 priming immunization
followed by an HIV-1 envelope boosting immunization were exposed to pools of overlapping peptides spanning the HIV-1 envelope protein and the fractions of CD4+ or CD8+ T cell
producing IFN-γ, TNF-α, or IL-2 are shown in the left panel. Functional proﬁles of the vaccine-elicited envelope-speciﬁc CD4+ T cells are shown as themean values in pie charts in the
right panel. (B) Expression of IFN-γ, TNF-α, or IL-2 by CD4 + T cells from a representative rhesusmonkey following rAd5 prime and envelope protein boost immunization is shown in
the left panels. Expression of CD28 on envelope-speciﬁc cytokine-producing CD4+ T cells from a representative rhesus monkey is shown in the middle panel. Expression of CD28 on
these envelope-speciﬁc cytokine-producing CD4+ T cells is presented as mean±SEM in the right panel.
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that these T cell vaccine strategies generated CD28+ memory CD4+ T
cell populations that home to the lymphoid tissue.
We have previously shown that both the magnitude and
functional proﬁle of the virus-speciﬁc CD8+ T cells generated by
vaccination were associated with control of viral replication followingSHIV-89.6P challenge (Sun et al., 2008). In the current study, we found
that neither the magnitudes nor the functional proﬁles of the virus-
speciﬁc CD4+ T cells generated by vaccination were associated with a
preservation of CD4+ T cells or control of viral replication following
SHIV-89.6P challenge. It is now clear that CD8+ T cell responses are
associated with the containment of HIV/SIV replication in acute
54 Y. Sun et al. / Virology 406 (2010) 48–55infection, and they are also important for the maintenance of viral
control during chronic infection (Borrow et al., 1997; Schmitz et al.,
1999). CD4+ T cells provide help for B cell responses and maintain
effective cytotoxic T lymphocytes (CTL) (Kalams and Walker, 1998).
Functional CD4+ T cells are also required at the time of immune
priming for the development of long-term memory CD8+ T cells
(Janssen et al., 2003; Shedlock and Shen, 2003). Therefore, although
we did not document a direct association between the magnitudes of
the virus-speciﬁc CD4+ T cell population generated by vaccination
and the control of viral replication after challenge, we previously
reported that a survival advantagewas associatedwith themagnitude
of the virus-speciﬁc CD4+ T cell responses generated by vaccination
and also associated with the preservation of the virus-speciﬁc CD4+ T
cell responses following SIVmac251 infection (Sun et al., 2006). The
difference between these ﬁndings in the setting of a SHIV-89.6P and
an SIVmac251 infection may reﬂect differences in the pathogenic
consequences of a CXCR4-tropic and a CCR5-tropic lentivirus.
We used archived PBMCs from 51 rhesus monkeys from previously
reported studies that received different homologous or heterologous
prime–boost immunizations. There are therefore caveats that should be
acknowledged when interpreting these ﬁndings. The differences in the
immunization and challenge schedules for each experimental group of
monkeys in these studies might have inﬂuenced the functional T cell
data. In addition, the administration of the IL-2/Ig plasmid during DNA
vaccine priming in the DNA/DNA and DNA/rMVA groups may have led
to augmented immune responses that were capable of controlling
viremia and preventing disease progression following a SHIV-89.6P
challenge. Nevertheless, the ﬁndings in the present study demonstrate
that vaccine strategies that include recombinant MVA or recombinant
Ad5 vectors can elicit robust CD4+ T cell responses.
In the current study, we found that rhesus monkeys primed with
rAd5 showed a dramatic expansion of virus-speciﬁc CD4+ T cell
responses following an envelope protein boost. In addition, boosting
with MF59-adjuvanted protein elicited a further expansion of the
polyfunctional Env-speciﬁc CD4+ T cell responses, with 3/4 of the
responses made up of either cytokine double-positive or triple-
positive CD4+ T cells. Further, these polyfunctional Env-speciﬁc CD4+
T cell responses were well preserved 12 weeks following the protein
boost immunization. These results indicate that a protein boost
immunization induced durable, high-frequency envelope-speciﬁc
CD4+ T cell responses with polyfunctional repertoires.
Materials and methods
Selection of rhesus monkeys
Heparinizedblood sampleswere obtained fromMamu-A*01− rhesus
monkeys (Macacamulatta). All animals were maintained in accordance
with the NIH Guide to the Care and Use of Laboratory Animals (National
Research Council, 1996) and with the approval of the Institutional
Animal Care and Use Committee of Harvard Medical School and the
National Institutes of Health.
Immunization and challenge of rhesus monkeys
Archived PBL from 51 rhesus monkeys from previously reported
studieswere assigned to six experimental groups that received different
homologous or heterologous prime–boost immunizations (Letvin et al.,
2004, 2006; Santra et al., 2004, 2007,2009; Seamanet al., 2005). Plasmid
DNA, rAd5 and rMVA vaccine vectors were constructed as previously
described and all vaccine regimenswere administered by intramuscular
injection using a needle-free Biojector system. In the rAd5-protein
group, six monkeys received 100 μg of SF162 (delta V2) gp140 protein
administered with MF59 adjuvant as a boosting immunization (Burke
et al., 2009). The immunization and challenge schedules for each
experimental group ofmonkeys are summarized in Table 1. Five groupsof experimentally vaccinated and 14 Mamu-A*01− control monkeys
were challenged intravenously with ﬁfty 50% monkey infectious doses
of pathogenic SHIV-89.6P from the same virus stock.
CD4+ T lymphocyte counts and plasma viral RNA levels
Peripheral blood CD4+ T lymphocyte counts were calculated by
multiplying the total lymphocyte countby thepercentage of CD3+CD4+
Tcells determinedbymAb stainingandﬂowcytometric analysis. Plasma
viral RNA levels were measured by an ultra-sensitive branched DNA
ampliﬁcation assaywith a detection limit of 125 copies perml (Siemens
Diagnostics, Berkeley, CA).
Antibodies
The antibodies used in this study were directly coupled to
ﬂuorescein isothiocyanate (FITC), phycoerythrin (PE), phycoerythrin–
Texas red (ECD), peridinium chlorophyll protein-Cy5.5 (PerCP-Cy5.5),
phycoerythrin-Cy7 (PE-Cy7), AmCyan, Paciﬁc Blue®, allophycocyanin
(APC), Alexa Fluor® 700 and Quantum-Dot 605. All reagents were
validated and titrated using rhesus monkey PBL. The following mAbs
were used: anti-TNF-α-FITC (MAb11; BD Biosciences, San Jose, CA),
anti-β7-PE (FIB504; BD Biosciences), anti-CD95-ECD (DX2; BD Bios-
ciences), anti-CD28-PerCP-Cy5.5 (L293; BDBiosciences), anti-IFN-γ-PE-
Cy7 (B27; BD Biosciences), anti-CD3-Paciﬁc Blue® (SP34-2; BD
Biosciences), anti-IL-2-APC (MQ1-17H12; BD Biosciences), anti-CD8α-
Alexa Fluor® 700 (RPA-T8; BD Biosciences), and anti-CD4-Qantum-Dot
605 (unconjugated anti-CD4antibodywasobtained fromBDBioscience,
Qantum-Dot 605 was obtained from Invitrogen, Carlsbad, CA). A violet
ﬂuorescent reactive dye (ViViD; Invitrogen) was also used as a viability
marker to exclude dead cells in the analysis.
PBL stimulation and intracellular cytokine staining
Puriﬁed PBL were isolated from EDTA-anticoagulated blood and
frozen in the vapor phase of liquid nitrogen. Cells were later thawed and
allowed to rest for 6 h at 37 °C in a 5% CO2 environment. The viability of
these cells was N90%. PBL were then incubated at 37 °C in a 5% CO2
environment for 6 h in the presence of RPMI/10% fetal calf serum alone
(unstimulated), a pool of 15-mer Gag or Env peptides (2 μg/ml of each
peptide; AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH, Germantown, MD), or staphylococcal enterotoxin B
(SEB) (5 μg/ml, Sigma-Aldrich, St. Louis, MO) as a positive control. All
cultures contained Monensin (GolgiStop; BD Biosciences) as well as
1 μg/ml anti-CD49d (BD Biosciences). Anti-CD28 and anti-CD49dmAbs
are usually used to costimulate T cell activation in intracellular cytokine
staining assays. Since we included anti-CD28 antibody in our staining
panel ofmAbs,weexcluded the anti-CD28mAb in the stimulation phase
of the assay to avoid the down-regulation of this molecule. The cultured
cells were stained with mAbs speciﬁc for cell surface molecules
including CD3, CD4, CD8, CD28, CD95, and β7. After ﬁxing with
Cytoﬁx/Cytoperm solution (BD Biosciences), cells were permeabilized
and stained with antibodies speciﬁc for IFN-γ, TNF-α, and IL-2. Labeled
cells were ﬁxed in 1% formaldehyde-PBS.
Flow cytometric analysis
Sampleswere collected on a BD LSRIIﬂow cytometer (BDBiosciences)
and analyzed using FlowJo software (Tree Star, Ashland, OR). Approx-
imately 500,000 to 1,000,000 events were collected per sample. Doublets
wereexcludedby forwardscatter (FSC)-areaversusFSC-height.Deadcells
were excluded by their stainingwith amine reactive dye. CD4+ and CD8+
T cells were determined by their expression of CD3, CD4, or CD8.
Functional analysesweredonebyplotting the expressionof each cytokine
molecule against another, and a boolean combination of single functional
gates was generated using FlowJo software. The frequency of cells
55Y. Sun et al. / Virology 406 (2010) 48–55producing IFN-γ, TNF-α, and IL-2, either individually or in any
combination, was determined from the FlowJo, formatted in PESTLE,
and analyzed using SPICE software (both PESTLE and SPICE software
were provided by M. Roederer, Bethesda, NIH). All values used for
analysis are background subtracted. Responses were considered
positive when the percentage of total cytokine-producing cells was at
least twice that of the background.
Statistical analyses
Statistical analyses and graphical presentationswere computedwith
GraphPad Prism. The Kruskal–Wallis test for multiple groups (or the
Mann–Whitney test for two groups) was used to compare the cellular
immune responses of the different groups of experimental animals.
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